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An elegant paper by Anchoori and colleagues in this issue ofCancer Cell describes an irreversible inhibitor of
Rpn13, one of the ubiquitin receptors on the 26S proteasome that is nonessential for proteasome function in
most normal tissues, but is overexpressed in many solid tumors.The proteasome is an essential compo-
nent of the protein quality control appa-
ratus in every eukaryotic cell. The load on
the proteasomes in cancer cells is higher
than in their nonmalignant counterparts,
causing them to be more sensitive to pro-
teasome inhibitors (Cenci et al., 2011).
Since the introduction of bortezomib
(Velcade) for the treatment of multiple
myeloma 10 years ago, proteasome inhib-
itors have attracted major interest from
drug companies and academic labora-
tories. Most companies have focused
their efforts on designing inhibitors of the
chymotrypsin-like sites of the 20S proteo-
lytic core, which play the major role in
protein breakdown and are the primary
targets of bortezomib. Last year, the
Food and Drug Administration (FDA)
approved a second proteasome inhibitor,
carfilzomib (Kyprolis), for the treatment of
relapsedand refractorymultiplemyeloma.
Four additional inhibitors are currently un-
dergoing clinical trials (Molineaux, 2012).
The 26S proteasome is an unusual
target, because it presents multiple op-
portunities for therapeutic intervention. In
addition to three pairs of distinct activesites within its proteolytic core, it contains
multiple targets within its 19S regulatory
complexes (Figure 1). The function of the
regulatory complex is to recognize pro-
teins marked for degradation by the
attachment of ubiquitin chains, unfold
these proteins, and recycle ubiquitin.
Each 19S complex contains six ATPases,
three de-ubiquitylating enzymes, and at
least two ubiquitin receptors, all of which
are potential targets for therapeutic inter-
vention. The elegant study in this issue of
Cancer Cell by Anchoori et al. (2013) de-
scribes the first inhibitor of one of the ubiq-
uitin receptors, Rpn13.
Following up on their earlier study,
which identified an amino acid substituted
1,3-diphenyl-1-one (chalcone) as an in-
hibitor of the ubiquitin-proteasome sys-
tem that killed cervical cancer cells
(Anchoori et al., 2011), Roden and his col-
laborators set out to improve the potency
and bioavailability of their compound.
This effort led to the discovery of RA190,
which induced apoptosis in bortezomib-
resistant myeloma cells and several cervi-
cal and ovarian cancer cell lines. Although
it induced an accumulation of ubiquity-lated proteins and stabilized luciferase
reporter substrates, hallmarks of protea-
some inhibition, it failed to inhibit any of
the three active sites of the 20S proteo-
lytic core. A combination of chemical
modification and washout experiments
convinced the authors that RA190 is an
irreversible inhibitor, allowing them to
convert it into an activity-based probe.
This probe labeled just one polypeptide
in the cell, which, through a series of
elegant biochemical experiments, was
identified as Rpn13. Further analysis by
site-directed mutagenesis and nuclear
magnetic resonance (NMR) revealed that
Cys-88 in the Rpn13 ubiquitin-binding
domain is modified by the drug. Surpris-
ingly, Cys-88 is located on the side of
the domain opposite to the ubiquitin-
binding site, in the region that forms the
interface with another Rpn13 domain,
the Uch37 binding domain (Figure 1A).
Based on analysis of available NMR
data, the authors concluded that RA190
abrogates interactions between the two
Rpn13 domains. Further mechanistic
studies are needed to understand how
this conformational change disruptsDecember 9, 2013 ª2013 Elsevier Inc. 691
Figure 1. A Model for the Consequences of Rpn13 Inhibition
(A) RA190 binds to Rpn13 at the interdomain region and disrupts interactions between the ubiquitin-bind-
ing domain and Uch37-binding domain. Rpn13 is anchored to the proteasome through interaction with
Rpn2 (Husnjak et al., 2008; Schreiner et al., 2008). The RA190 binding site is closer to the Rpn2-interacting
region than to the Ub-binding site.
(B) Overexpression of Rpn13 in tumor cells presumably results in both 19S regulatory complexes contain-
ing this subunit as opposed to the one 19S complex occupied by Rpn13 in normal cells. Rpn13 inhibition is
lethal to tumor cells but is tolerated by normal cells because Rpn10 is sufficient to carry out the ubiquitin
recognition functions.
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the proteasome.
Finally, Anchoori et al. (2013) performed
extensive animal studies of RA190.
Although it was less potent than bortezo-
mib in a cellular assay, RA190 was orally
bioavailable, had a promising safety pro-
file, did not suppress the immune system,
and appeared to induce regression of
xenograft myeloma tumors in NOG mice.
It was able to significantly reduce the
growth of ovarian tumors in nude mice,
and HPV16 E6 and E7 transformed syn-
geneic TC-1 tumors in B6 mice, although
it did not induce any tumor regression in
these solid tumor models. Higher doses
and more frequent drug administration692 Cancer Cell 24, December 9, 2013 ª201were used to treat the myeloma. Could
regression of solid tumors be achieved if
they were treated with the same high
doses of the drug as myeloma-bearing
mice? On the other hand, the toxicity
data were generated with lower and less
frequent doses used in the solid tumor
models. Would the compound safety pro-
file be the same if more intense dosing
was used? If not, can combinations with
synergistic activity that induces tumor
regression be found? In this regard, it is
worth mentioning that RA190 exhibited
synergistic activity with bortezomib in
HeLa cells. Furthermore, unlike bortezo-
mib and the majority of chemotherapeutic
agents, RA190 does not appear to sup-3 Elsevier Inc.press the immune system, hence the
authors raise the possibility of combining
it with therapeutic vaccines.
This study is highly significant, because
this compound has activity in bortezomib-
resistant multiple myeloma in vitro and
because it demonstrates the potential of
Rpn13 inhibitors for the treatment of solid
tumors. Despite the high initial response
rate of bortezomib-containing regimens
in myeloma patients, all of these patients
eventually develop resistance to these
regimens and all other FDA-approved
antimyeloma agents. In this regard, the
ability of RA190 to overcome bortezomib
resistance in the in vitro-adapted cells is
encouraging.
The reason for the exquisite sensitivity
of myeloma cells to proteasome inhibitors
is an exceptionally high load on the pro-
teasome in these malignant plasma cells
(Cenci et al., 2011), which are the biggest
protein secretors in the body. Although
the load on the proteasomes in other he-
matologic malignancies and solid tumors
is higher than in normal tissues, the differ-
ence may not be sufficient to provide a
therapeutic window. The insufficient ther-
apeutic window may be one of the rea-
sons for the failure of bortezomib and
other inhibitors of proteolytic sites of the
20S core to achieve responses in solid
tumors. Rpn13 is encoded by the
ADRM1 gene, which is overexpressed in
lung, ovarian, colon, liver, kidney,
bladder, and stomach cancers (Pilarsky
et al., 2004). ADRM1 amplification in
ovarian cancers correlates significantly
with shorter time to recurrence and death
(Fejzo et al., 2013). ADRM1 was overex-
pressed in 46% of colorectal cancers
and significantly correlated with lymph
node metastasis (Chen et al., 2009).
Although many other proteasome sub-
units are overexpressed in tumors, most
of them are essential to normal tissues.
Rpn13 is one of the few nonessential pro-
teasome subunits. Homozygous Adrm1
knockout mice are viable, although they
are infertile and show increased body fat
content and elevated T cell numbers
(Al-Shami et al., 2010). The Rpn13-KKD
yeast strain, which carries a genomic
copy of an Rpn13 allele that lacks the abil-
ity to bind ubiquitin, shows phenotypic
defects only under conditions that in-
crease the load on proteasomes (Husnjak
et al., 2008). Presumably, another ubiqui-
tin receptor, Rpn10, is sufficient to carry
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tions when proteasomes are not over-
loaded. These data suggest that an
Rpn13 inhibitor should have a wider ther-
apeutic window than inhibitors of proteo-
lytic sites (Figure 1B). Taken together, this
study by Anchoori et al. (2013) validates
the proteasome ubiquitin receptor
Rpn13 as a druggable target and opens
a new road to extend the therapeutic
application of proteasome inhibitors to
the treatment of solid tumors.
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Lung cancers are divided into four types according to their histologic appearance. Therapeutic decisions are
partly based on histology. A recent study indicates that certain molecular alterations associate with histology
and that therapies directed to these molecular changes improve outcome, indicating that genomic informa-
tion should be incorporated into future tumor classification.Lung cancers are the most common
cause of cancer death worldwide. For
many years, lung cancer histologies
have been determined according to the
World Health Organization (WHO) clas-
sification based primarily on the light
microscopic appearance of the malignant
cells (adenocarcinoma, squamous carci-
noma, large cell carcinomas, and small
cell carcinoma). The most recent pro-
posed WHO modifications reclassified
some adenocarcinomas into adeno-
carcinoma in situ, incorporating some
prior bronchioalveolar carcinomas and
minimally invasive or invasive carcinomas
with specification of the predominant
histologic pattern (Travis et al., 2011). In
past years, small cell carcinomas mixedwith large cell carcinoma (the so-called
22/40 subtype) were distinct within the
small cell classification, but later revision
classified these as either small cell car-
cinoma or large cell undifferentiated
carcinomas with neuroendocrine features
(Travis et al., 2004). Mixed small cell/
adenocarcinoma remained as a histologic
designation. Tumors where no differ-
entiation could be determined by histo-
logic appearances or immunohisto-
chemical staining for adenocarcinoma
or squamous cell carcinoma features
were designated as large cell undifferenti-
ated carcinomas. The WHO classification
is scheduled for revision in 2014.
Enter genomic testing. The paper
from the Clinical Lung Cancer GenomeProject (CLCGP) and Network Genomic
Medicine (NGM) team sheds consider-
able light on the relationship between
histologic appearance and genomic
abnormalities [The Clinical Lung Genome
Project (CLCGP) and Network Genomic
Medicine (NGM), 2013]. The authors
report that almost all cases of large cell
undifferentiated carcinomas could be
reclassified and assigned to one of the
other histologic types based on both
immunohistochemistry and genomic
alterations. These findings have con-
siderable relevance to patients with a his-
tologic diagnosis of large cell carcinoma.
Clinically, these patients are currently
grouped with patients with adenocarci-
nomas and treated with cytotoxicDecember 9, 2013 ª2013 Elsevier Inc. 693
